Related Experiment Video
Updated: Mar 20, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Chlamydia psittaci pneumonia in a patient using ustekinumab therapy for Crohn's disease
J A M C Dirks1, L Mulder2, K Burgers3
1Department of Medical Microbiology (and reference laboratory for human Chlamydia infections from animal origin), Zuyderland Medical Center, Sittard-Geleen, the Netherlands.
Background:
Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin-12 and interleukin-23, is widely used for immune-mediated diseases such as Crohn's disease. By modulating Th1 and Th17 pathways, ustekinumab may increase susceptibility to intracellular pathogens. We report the first case of Chlamydia psittaci pneumonia in a patient treated with ustekinumab.
Case Summary:
A 27-year-old woman with Crohn's disease presented with severe community-acquired pneumonia, progressive hypoxemia, and pulmonary embolism 3 weeks after initiating ustekinumab therapy. Despite broad-spectrum antibiotics, clinical improvement was limited. Her exposure history revealed contact with multiple pet birds, several of which died recently. Polymerase chain reaction testing confirmed C. psittaci genotype A infection. Targeted treatment with doxycycline led to clinical recovery. Ustekinumab therapy was temporarily postponed.
Conclusion:
This case highlights a potential association between ustekinumab and susceptibility to C. psittaci, a zoonotic intracellular pathogen. It underscores the importance of exposure history and considering atypical pathogens in immunocompromised patients. Clinicians should maintain vigilance for opportunistic infections in individuals receiving targeted biologic therapies.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Bacterial Phylum Chlamydiae
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

